<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202979</url>
  </required_header>
  <id_info>
    <org_study_id>039(B)PO16143</org_study_id>
    <secondary_id>2016-002772-27</secondary_id>
    <nct_id>NCT03202979</nct_id>
  </id_info>
  <brief_title>Trazodone in Painful Diabetic Neuropathy</brief_title>
  <official_title>Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to collect preliminary information on the effect of low doses of
      trazodone on pain intensity in patients with painful diabetic neuropathy and to evaluate the
      neuropathic pain symptoms, anxiety, sleep, quality of life, safety and tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled, double-dummy, dose finding, parallel
      group, multicentre, international, prospective, pilot study.

      The present study is planned to assess the efficacy and the safety of an 8-week treatment
      period with low doses of trazodone (30 mg daily or 60 mg total daily, respectively)
      administered to patients affected by painful diabetic neuropathy.

      Gabapentin will be administered together with the investigational drug in open label
      conditions in order to assure an effective pharmacological treatment to all patients. A slow
      titration of gabapentin will be applied in this trial in order to control possible side
      effects when co-administered with trazodone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo controlled, double-dummy, dose finding, multicentre, international, prospective, pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The present study will be performed in double blind conditions. During the study, neither the Investigator nor the patient will be aware of the treatment assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Day 56</time_frame>
    <description>Change from baseline of item 5 score in BPI-SF numering scale after 56 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 63</time_frame>
    <description>Change from baseline of item 5 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 3 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 3 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 4 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 4 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 5 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 6 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 6 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 8 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 8 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 9 score in Brief Pain Inventory Short Form (BPI-SF) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of item 9 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Pain Symptom Inventory (NPSI) scale</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of total score in NPSI scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-item Short-Form Health Survey (SF-36)</measure>
    <time_frame>Baseline - Day 56</time_frame>
    <description>Change from baseline of SF-36 after 56 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline of total score in HAM-A scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Assessment by patient of the overall efficacy and tolerability by PGIC after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leeds Sleep Evaluation Questionnaire (LSEQ)</measure>
    <time_frame>Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.</time_frame>
    <description>Change from baseline in LSEQ after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>9 weeks</time_frame>
    <description>Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trazodone 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trazodone 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone 20 mg</intervention_name>
    <description>Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.
After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>TritticoÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone 10 mg</intervention_name>
    <description>Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.
In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).
After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>TritticoÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.
After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patient of any ethnic origin between 18 and 75 years of age (limits
             included).

          2. Patient with painful diabetic symmetric polyneuropathy manifesting with distally
             distributed neuropathic pain.

          3. Stable glycaemic control with a value of HbA1c â¤ 10% at Screening Visit.

          4. Pain persisting for at least 3 months.

          5. Neuropathic pain confirmed by DN4 score â¥ 4 at Screening Visit.

          6. BPI-SF 24-hour average pain score (item 5) â¥ 4 at Screening Visit and Baseline Visit.

          7. Patient who is currently not receiving treatment for diabetic neuropathic pain or
             patient who is receiving treatment, with drug/s other than gabapentin, and have
             completed the required washout.

          8. Women of childbearing potential must have a negative pregnancy test at Screening Visit
             and have to agree not to start a pregnancy from the signature of the informed consent
             up to thirty days after the last administration of the investigational product, using
             an appropriate birth control method, such as combined estrogen and progestogen
             containing hormonal contraception (e.g. oral, intravaginal, transdermal),
             progestogen-only hormonal contraception (e.g. oral, injectable, implantable),
             intrauterine device (IUD) or intrauterine hormone- releasing system (IUS) in
             combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual
             abstinence.

          9. Legally capable to give their consent to participate in the study and available to
             sign and date the written informed consent.

        Exclusion Criteria:

          1. Known hypersensitivity to trazodone or gabapentin or their excipients.

          2. Other forms of neuropathic pain or non-neuropathic pain (included but not limited to
             peripheral arterial disease, radiculopathy, mononeuropathy, proximal motor neuropathy,
             post-operative pain, etc).

          3. Concomitant treatment with other medications for pain management.

          4. Concomitant treatment with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir,
             indinavir) or drugs known to prolong QT interval.

          5. Use of trazodone or gabapentin in the previous 3 months.

          6. Clinically significant abnormalities on physical examination, vital signs, ECG,
             laboratory tests at Screening Visit that in the opinion of Investigator would
             compromise patient's participation in the study.

          7. Active foot ulcer or previous major limb amputation.

          8. Myocardial infarction or angioplasty or by-pass graft procedures within the past 6
             months.

          9. Patient with increased risk of Torsade de Pointes (e.g. family history of long QT
             syndrome) or QTcF value higher than 450 msec (male) and QTcF value higher than 470
             msec (female) at Screening Visit.

         10. Transient ischemic attack or cerebral vascular accident within the past 6 months.

         11. GFR value &lt; 60 ml/min calculated with MDRD formula.

         12. Significant liver disease, defined as known active hepatitis or elevated liver enzymes
             over 3 fold the upper normal limit of laboratory normal ranges.

         13. Patient with latent or known hereditary problems of galactose intolerance or the Lapp
             lactase deficiency or glucose-galactose malabsorption.

         14. Positive urine drug screen for CNS active drugs (cocaine, opioids, amphetamines and
             cannabinoids) a Screening Visit.

         15. Positive present history of glaucoma.

         16. Hyperthyroidism, even if pharmacologically corrected.

         17. Significant mental disorders.

         18. History of seizure events other than a single childhood febrile seizure.

         19. History of alcohol or psychoactive substance abuse or addiction.

         20. Patient suffering from adrenal hypofunction (e.g. Addison's disease).

         21. Women during pregnancy or lactation period.

         22. Inability to comply with the protocol requirements, instructions or study-related
             restrictions (e.g. uncooperative attitude, inability to return for study-visits,
             improbability of completing the clinical study, etc).

         23. Subject involved in the conduct of the study (e.g. Investigator or his/her deputy,
             first grade relatives, pharmacist, assistant or other personnel, etc).

         24. Participation to an interventional clinical trial within 3 months prior to Screening
             Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Lipone</last_name>
    <phone>+ 39 06 91045349</phone>
    <email>p.lipone@angelini.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Del Vecchio</last_name>
    <phone>+ 39 06 91045311</phone>
    <email>a.delvecchio@angelini.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NEUROHK s.r.o.</name>
      <address>
        <city>Chocen</city>
        <zip>565 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Valis, MD</last_name>
      <email>valismar@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Valis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Litnea s.r.o. Neurologicka ambulance</name>
      <address>
        <city>Litomerice</city>
        <zip>412 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marketa Cee, MD</last_name>
      <email>Cee.jiri@tiscali.cz</email>
    </contact>
    <investigator>
      <last_name>Marketa Cee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurosanatio s.r.o.</name>
      <address>
        <city>Litomysl</city>
        <zip>570 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Zinek, MD</last_name>
      <email>karel.zinek@senam.cz</email>
    </contact>
    <investigator>
      <last_name>Karel Zinek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MP-neuro s.r.o. Poliklinika Modry pavilon</name>
      <address>
        <city>Ostrava</city>
        <zip>710 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danuse Roubcova, MD</last_name>
      <email>danuse.roubcova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Danuse Roubcova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubickeho kraje a.s. Pardubicka nemocnice NeurologickÃ¡ klinika</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edvard Ehler, MD</last_name>
      <email>eda.ehler@tiscali.cz</email>
    </contact>
    <investigator>
      <last_name>Edvard Ehler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetologicka ambulance Milan Kvapil s.r.o.</name>
      <address>
        <city>Praha 4</city>
        <zip>149 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Bartaskova, MD</last_name>
      <email>dagmar.bartaskova@centrum.cz</email>
    </contact>
    <investigator>
      <last_name>Dagmar Bartaskova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestra Clinics s.r.o.</name>
      <address>
        <city>Rychnov nad KneÅ¾nou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladislav Pazdera, MD</last_name>
      <email>pazdera@vestraclinics.org</email>
    </contact>
    <investigator>
      <last_name>Ladislav Pazdera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz BelgyÃ³gyÃ¡szati Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos Kis, MD</last_name>
      <email>kis.janos.tibor.dr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Janos Kis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem AOK I. sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Takacs, MD</last_name>
      <email>takacs.istvan@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Istvan Takacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Oktatokorhaz es Rendelointezet Diabetesz Gondozo</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EleonÃ³ra Harcsa, MD</last_name>
      <email>harcsa.eleonora@mfkh.hu</email>
    </contact>
    <investigator>
      <last_name>EleonÃ³ra Harcsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz I. sz. Belgyogyaszati Osztaly</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaly Dudas, MD</last_name>
      <email>mihalyd@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mihaly Dudas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz II. sz. Belgyogyaszati Osztaly</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaly Gurzo, MD</last_name>
      <email>gurzom@kmk.hu</email>
    </contact>
    <investigator>
      <last_name>Mihaly Gurzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont I. Sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Takacs, MD</last_name>
      <email>takacs.robert@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Robert Takacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silmedic Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Palka-Kisielowska, MD</last_name>
      <email>IKISIELOWSKA@SILMEDIC.PL</email>
    </contact>
    <investigator>
      <last_name>Ilona Palka-Kisielowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pro Familia Altera Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danuta Wronska, MD</last_name>
      <email>dwronska@profamilia.katowice.pl</email>
    </contact>
    <investigator>
      <last_name>Danuta Wronska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Neuromed M. i M. Nastaj Sp. P.</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Nastaj, MD</last_name>
      <email>marcinnastaj@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcin Nastaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RCMed OddziaÅ Sochaczew</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Fengler-Czeczko, MD</last_name>
      <email>malgorzata.fenglerczeczko@rcmed.com.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Fengler-Czeczko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeka SÅawomir Niepubliczny ZakÅad Opieki Zdrowotnej &quot;Nasz Lekarz&quot; Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ocicka-Kozakiewicz, MD</last_name>
      <email>a.ocicka@naszlekarz.com.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Ocicka-Kozakiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NBR Polska Tomasz Klodawski</name>
      <address>
        <city>Warszawa</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Klodawska, MD</last_name>
      <email>katarzyna.klodawska@nbrpolska.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Klodawska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bozena Zapecka- Dubno, MD</last_name>
      <email>bozenazapeckadubno@medycynakliniczna.pl</email>
    </contact>
    <investigator>
      <last_name>Bozena Zapecka- Dubno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trazodone</keyword>
  <keyword>Placebo</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

